Wockhardt Discovery is engaged in the pursuit of developing antibiotics with the vision of targeting the realm of unmet medical need over the last 20 years. Thorough research by discovery team yielded in various drugs which are in various stages. These drugs have shown promising results in the treatment of many serious bacterial infections, some with no currently available treatment for infections in respiratory, urinary tract, blood and abdominal regions.
These products, currently in various phases of clinical research, have already received the coveted Qualified Infectious Disease Product (QIDP) status from US FDA. This QIDP receipt is a critical success for Wockhardt as it becomes the entity with the highest number of QIDP approvals globally.
Key Features:
- Products: Review the current drug pipeline developed by Wockhardt Ltd
- Publications: Read the various papers published by Wockhardt Ltd
- Posters: View the posters published at various Conferences
- Conferences: Browse through the list if Conferences that Wockhardt has participated and the related posters